Is MRMD a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for MariMed (MRMD) rests on Branded wholesale growth: MariMed's most distinctive asset is its brand portfolio, not its store count. The bear case rests on the main risk is leverage relative to a small equity value. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
MRMD key stats
At $0.05 on November 20, 2026, MariMed (MRMD) has a market cap of $20M.
- Market cap
- $20M
- Price to book
- 0.5
- Beta
- 1.55
Market cap, P/E and yield are measured at the $0.05 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with MariMed (MRMD)?
The last two weeks for MariMed, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- MRMD closed at $0.05 on November 20, 2026, down 32.9% over the past five trading days (from $0.07).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
MariMed Inc. is a multi-state cannabis operator headquartered in Norwood, Massachusetts. It runs cultivation and production facilities and a chain of dispensaries under the Panacea Wellness and Thrive names, with its core footprint in Massachusetts, Illinois, Maryland, Delaware and Ohio. The company is best known for its branded products rather than its stores: Betty's Eddies fruit chews, Kalm Fusion drinks and tablets, Bubby's Baked, Vibations and the Nature's Heritage flower line. Management says its brands reach about 85% of dispensaries in its core markets, and wholesale to other retailers is a growing share of sales. It has also licensed its brands into Maine and exited Missouri. Recent results show a business that is growing slowly while margins compress. Revenue for 2025 was ~$159.8M, up about 1% from ~$157.7M in 2024. In 2026 the top line picked up: Q1 revenue was ~$39.5M and Q2 reached a record ~$41.9M, up about 6% year over year, which puts trailing revenue near ~$164M. Profitability moved the other way. Q2 adjusted EBITDA was ~$3.9M (about a 9% margin) versus ~$4.8M a year earlier, gross margin slipped to roughly 39% from 40%, and the GAAP net loss widened to ~$3.6M from ~$1.4M. A wholesale customer that went bankrupt added a write-off. Q3, reported November 11, 2026, set another revenue record at ~$44.2M, up 8.5% from ~$40.8M a year earlier, with wholesale at ~$19.5M and retail at ~$24.5M, which lifts trailing revenue to ~$167M. Adjusted EBITDA was ~$4.7M (a 10.5% margin) against ~$5.1M (12.6%) a year earlier, GAAP gross margin was 38.8% versus 40.1%, and the GAAP net loss was ~$3.5M versus ~$2.9M. The investment picture is mostly about the balance sheet and the listing. At ~$0.05 a share on November 20, 2026 the equity is worth only about ~$19M, while mortgages and notes payable were ~$78.2M at September 30, 2026, against ~$10.4M of cash, which the company called its strongest cash position in two years. MariMed also carries large income taxes payable from Section 280E and roughly ~$7M of disputed IRS tax liens. In early 2026 it restructured a ~$14.7M Series B preferred obligation into ~$8M of notes due 2028 and 2031 plus new preferred stock, and its auditors have not issued a going-concern warning. At a special meeting on October 28, 2026 shareholders approved a reverse split of 1-for-50 to 1-for-100, aimed at a possible US exchange listing; the Q3 release did not give a final ratio or effective date. That is the main event-driven catalyst, alongside federal rescheduling. The stock is down about 48% year to date and about 40% over one year.
The bull case for MRMD
1. Branded wholesale growth
MariMed's most distinctive asset is its brand portfolio, not its store count. Betty's Eddies, Kalm Fusion, Bubby's Baked, Vibations and Nature's Heritage sell through roughly 85% of dispensaries in its core markets, and wholesale revenue grew about 11% in 2025, another ~6% sequentially in Q2 2026 and 8.1% year over year in Q3 2026 to ~$19.5M. In Q3 its branded products sold into 721 stores, up 13%, branded market share in core markets rose 150 basis points by industry data, and the company says Betty's Eddies is the top-selling edible brand in its core states. Wholesale lets the company grow without building new stores, and licensing deals such as the Maine arrangement extend the brands into states where it holds no license. The risk is price: wholesale flower and edibles prices keep falling in mature markets, so volume growth has to outrun price compression for this driver to lift profits rather than just revenue.
2. Delaware and Ohio retail expansion
Delaware launched adult-use sales in August 2025, and 2026 is the first full year MariMed earns from it, helped by the FSC Delaware acquisition it is still integrating. In Ohio, which legalized adult use in 2023, the company opened a Thrive dispensary in Columbus in September 2026 as its second store in the state. These are younger, less saturated markets than Massachusetts or Illinois, where prices have fallen hard. If Delaware and Ohio scale, they help explain how quarterly revenue climbed from ~$39.5M to ~$41.9M and then ~$44.2M in 2026; Q3 retail revenue rose 8.4% to ~$24.5M, with Thrive transactions up 7%. The offset is that new stores carry opening costs and take several quarters to reach mature margins.
3. Rescheduling and 280E tax relief
Section 280E bars cannabis companies from deducting normal business expenses, which is why MariMed carries large income taxes payable (around ~$29.6M at March 31, 2026) and a dispute with the IRS. An April 2026 Justice Department order moved state-licensed MEDICAL marijuana to Schedule III, which advisers read as ending 280E for qualifying medical sales from the 2026 tax year; MariMed's Q2 tax expense fell by an estimated ~$0.8M. Adult-use cannabis, which is most of MariMed's revenue, remains Schedule I pending a broader DEA rule. Full rescheduling would be the single largest swing factor for cash flow, but timing is uncertain and legal challenges are expected.
4. Reverse split and possible uplisting
MariMed trades on the OTCQB and the CSE, which keeps many institutional investors away and helps explain why the equity is valued at about ~$19M against ~$167M of revenue. At the October 28, 2026 special meeting holders approved a reverse split between 1-for-50 and 1-for-100, explicitly to meet minimum price requirements for a possible US national exchange listing; the exact ratio is left to the board, and as of the November 11 Q3 release no ratio or effective date had been disclosed. A split by itself changes nothing about the business, and the company says there is no assurance it will qualify. Major US exchanges have also historically been reluctant to list plant-touching cannabis companies, so any uplisting likely depends on federal policy as well as share price.
The bear case for MRMD
The main risk is leverage relative to a small equity value. Mortgages and notes payable were ~$78.2M at September 30, 2026, up from ~$72.7M at year-end 2025, against ~$10.4M of cash and quarterly adjusted EBITDA of only ~$3.6M to ~$4.7M. Covenant breaches could allow lenders to accelerate debt, as the 10-K warns. Tax is a second pressure point: large unpaid income taxes from 280E, ~$7M of disputed IRS liens and a required ~$100,000 monthly escrow tie up cash. Margins are trending down as wholesale prices fall, and a bankrupt wholesale customer already cost a write-off in 2026. The company has posted GAAP net losses (~$7.4M in the first half of 2026 and ~$3.5M more in Q3), and adjusted EBITDA margin fell to 10.5% in Q3 from 12.6% a year earlier. Federal rescheduling for adult use may be delayed or challenged. Dilution is possible through preferred stock, notes and equity raises, and a reverse split can be followed by further price declines, as often happens with OTC names. Finally, the stock is thinly traded on the OTC market, with a 52-week range of roughly ~$0.045 to ~$0.16 and a 45% decline over the three months to November 20, 2026, so quotes can move sharply on small volume.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding MRMD already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on MRMD
Too few analysts publish on MRMD for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The MRMD forecast page covers what coverage does exist.
How is MRMD valued?
Market cap, P/E and dividend yield at today's price are in the MRMD key stats above. The business figures below come from MariMed's reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$167M (Q3 2026 +8.5% YoY)
- Q3 2026 adjusted EBITDA: ~$4.7M (~10.5% margin)
- Net loss (TTM): ~$15.5M
- Mortgages and notes payable: ~$78.2M (cash ~$10.4M)
As of November 2026: On equity alone MariMed looks extremely cheap, at roughly 0.11x trailing sales. That figure misleads because debt is several times the market cap. Adding ~$78.2M of mortgages and notes and subtracting ~$10.4M of cash gives an enterprise value near ~$87M, or about 0.5x sales and roughly 5x an annualized ~$19M of Q3 adjusted EBITDA. That is in the range where small cannabis operators have traded, and it excludes the large income taxes payable, which behave like additional debt. GAAP earnings are negative, so a price-to-earnings ratio is not meaningful.
How do you decide if MRMD is a buy?
Whether MRMD is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MRMD indirectly through an index or sector ETF before adding more.
What would change your mind on MRMD
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Branded wholesale growth stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: the main risk is leverage relative to a small equity value fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the MRMD stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MRMD against your real portfolio and see your actual exposure before deciding.
Your questions about MariMed
Ask Walnut's AI anything about MRMD and see how it fits what you own.
FAQ
Is MRMD a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Branded wholesale growth, with revenue (ttm) at ~$167M (Q3 2026 +8.5% YoY). The bear case rests on the main risk is leverage relative to a small equity value. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell MRMD?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The main risk is leverage relative to a small equity value. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. Walnut is not an investment adviser.
What is the bull case for MRMD?
+
Branded wholesale growth. MariMed's most distinctive asset is its brand portfolio, not its store count.
What is the bear case for MRMD?
+
The main risk is leverage relative to a small equity value. Mortgages and notes payable were ~$78.2M at September 30, 2026, up from ~$72.7M at year-end 2025, against ~$10.4M of cash and quarterly adjusted EBITDA of only ~$3.6M to ~$4.7M. Covenant breaches could allow lenders to accelerate debt, as the 10-K warns. Tax is a second pressure point: large unpaid income taxes from 280E, ~$7M of disputed IRS liens and a required ~$100,000 monthly escrow tie up cash. Margins are trending down as wholesale prices fall, and a bankrupt wholesale customer already cost a write-off in 2026. The company has posted GAAP net losses (~$7.4M in the first half of 2026 and ~$3.5M more in Q3), and adjusted EBITDA margin fell to 10.5% in Q3 from 12.6% a year earlier. Federal rescheduling for adult use may be delayed or challenged. Dilution is possible through preferred stock, notes and equity raises, and a reverse split can be followed by further price declines, as often happens with OTC names. Finally, the stock is thinly traded on the OTC market, with a 52-week range of roughly ~$0.045 to ~$0.16 and a 45% decline over the three months to November 20, 2026, so quotes can move sharply on small volume.
What does MariMed do?
+
Multi-state cannabis operator running dispensaries and cultivation in Massachusetts, Illinois, Maryland and other states.
What would have to change for MRMD to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Branded wholesale growth) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the main risk is leverage relative to a small equity value) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
Why is MariMed stock only about five cents?
+
MariMed's price reflects a small equity cushion under a heavy load of obligations, not a business that stopped operating. The company generates roughly ~$167M of trailing revenue, but it carries ~$78.2M of mortgages and notes payable, large unpaid income taxes from Section 280E and about ~$7M of disputed IRS tax liens. Adjusted EBITDA has been shrinking as a share of sales, from about 12% to about 9% in Q2 2026 and 10.5% in Q3, and it posts GAAP net losses. The stock also trades over the counter, where institutional demand is limited, and has hundreds of millions of shares outstanding, so the per-share price is low. Over the past year it has ranged from roughly ~$0.16 down to ~$0.05. Shareholders approved a reverse split on October 28, 2026; if carried out, it would raise the per-share price mechanically without changing the company's total value.
Is MariMed going bankrupt or in receivership?
+
As of November 2026, there is no sign of bankruptcy, receivership or a declared default in MariMed's filings or news. Its auditors have not issued a going-concern warning, and the company continues to open stores, such as a new Thrive dispensary in Columbus, Ohio in September 2026. It did restructure a ~$14.7M Series B preferred obligation in early 2026, swapping it for ~$8M of notes due 2028 and 2031 plus new preferred stock, which pushed maturities out and recorded a small gain. Cash rose to ~$10.4M at September 30, 2026, and nine-month operating cash flow was ~$6.7M, up from ~$4.3M a year earlier. The 10-K includes standard warnings that covenant breaches could lead to default and accelerated debt. So the situation is a stretched balance sheet that management is actively managing, which is different from a company in liquidation, though the margin for error is thin.
What does MariMed actually sell?
+
MariMed is vertically integrated, meaning it grows cannabis, turns it into products and sells those products both in its own dispensaries and wholesale to other retailers. Its best-known brand is Betty's Eddies, a line of fruit chew edibles. Other brands include Kalm Fusion (drinks and tablets), Bubby's Baked (baked goods), Vibations (effervescent powders), InHouse and Nature's Heritage flower and concentrates. Its retail stores operate mainly under the Panacea Wellness and Thrive names. Its core states are Massachusetts, Illinois, Maryland, Delaware and Ohio, and it licenses brands into Maine. The company says its products reach about 85% of dispensaries in its core markets, which makes wholesale an increasingly important part of its revenue mix alongside its own stores.
Walnut is informational, not investment advice, and gives no verdict on MRMD. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.